vs

Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and IMMERSION CORP (IMMR). Click either name above to swap in a different company.

IMMERSION CORP is the larger business by last-quarter revenue ($372.9M vs $284.0M, roughly 1.3× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs -4.6%, a 100.9% gap on every dollar of revenue. On growth, IMMERSION CORP posted the faster year-over-year revenue change (750.4% vs 9.4%). Over the past eight quarters, IMMERSION CORP's revenue compounded faster (537.9% CAGR vs 17.5%).

Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.

Immersion Corporation is an Aventura, Florida based developer and licensor of touch feedback technology, also known as haptic technology. Immersion Corporation has been accused of being a patent troll. Founded in 1993 by Louis Rosenberg, it is currently headed by lawyer Francis Jose, who serves as both chief executive officer and general counsel.

ACAD vs IMMR — Head-to-Head

Bigger by revenue
IMMR
IMMR
1.3× larger
IMMR
$372.9M
$284.0M
ACAD
Growing faster (revenue YoY)
IMMR
IMMR
+741.0% gap
IMMR
750.4%
9.4%
ACAD
Higher net margin
ACAD
ACAD
100.9% more per $
ACAD
96.3%
-4.6%
IMMR
Faster 2-yr revenue CAGR
IMMR
IMMR
Annualised
IMMR
537.9%
17.5%
ACAD

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ACAD
ACAD
IMMR
IMMR
Revenue
$284.0M
$372.9M
Net Profit
$273.6M
$-17.0M
Gross Margin
90.8%
Operating Margin
6.1%
-2.8%
Net Margin
96.3%
-4.6%
Revenue YoY
9.4%
750.4%
Net Profit YoY
90.3%
-191.3%
EPS (diluted)
$1.61
$-0.57

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ACAD
ACAD
IMMR
IMMR
Q4 25
$284.0M
Q3 25
$278.6M
Q2 25
$264.6M
$372.9M
Q1 25
$244.3M
$471.3M
Q4 24
$259.6M
$616.2M
Q3 24
$250.4M
Q2 24
$242.0M
$95.5M
Q1 24
$205.8M
$43.8M
Net Profit
ACAD
ACAD
IMMR
IMMR
Q4 25
$273.6M
Q3 25
$71.8M
Q2 25
$26.7M
$-17.0M
Q1 25
$19.0M
$24.1M
Q4 24
$143.7M
$30.8M
Q3 24
$32.8M
Q2 24
$33.4M
$26.4M
Q1 24
$16.6M
$18.7M
Gross Margin
ACAD
ACAD
IMMR
IMMR
Q4 25
90.8%
Q3 25
92.2%
Q2 25
92.2%
Q1 25
91.7%
Q4 24
91.6%
Q3 24
92.5%
Q2 24
92.5%
Q1 24
88.8%
Operating Margin
ACAD
ACAD
IMMR
IMMR
Q4 25
6.1%
Q3 25
12.8%
Q2 25
12.2%
-2.8%
Q1 25
7.9%
7.5%
Q4 24
59.1%
11.4%
Q3 24
12.6%
Q2 24
12.6%
23.7%
Q1 24
7.4%
37.9%
Net Margin
ACAD
ACAD
IMMR
IMMR
Q4 25
96.3%
Q3 25
25.8%
Q2 25
10.1%
-4.6%
Q1 25
7.8%
5.1%
Q4 24
55.4%
5.0%
Q3 24
13.1%
Q2 24
13.8%
27.7%
Q1 24
8.0%
42.5%
EPS (diluted)
ACAD
ACAD
IMMR
IMMR
Q4 25
$1.61
Q3 25
$0.42
Q2 25
$0.16
$-0.57
Q1 25
$0.11
$0.73
Q4 24
$0.86
$0.93
Q3 24
$0.20
Q2 24
$0.20
$0.81
Q1 24
$0.10
$0.59

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ACAD
ACAD
IMMR
IMMR
Cash + ST InvestmentsLiquidity on hand
$177.7M
$161.4M
Total DebtLower is stronger
$103.1M
Stockholders' EquityBook value
$1.2B
$298.1M
Total Assets
$1.6B
$1.1B
Debt / EquityLower = less leverage
0.35×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ACAD
ACAD
IMMR
IMMR
Q4 25
$177.7M
Q3 25
$258.0M
Q2 25
$253.6M
$161.4M
Q1 25
$217.7M
$153.9M
Q4 24
$319.6M
$159.3M
Q3 24
$155.1M
Q2 24
$177.1M
$133.4M
Q1 24
$204.7M
$179.1M
Total Debt
ACAD
ACAD
IMMR
IMMR
Q4 25
Q3 25
Q2 25
$103.1M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ACAD
ACAD
IMMR
IMMR
Q4 25
$1.2B
Q3 25
$917.3M
Q2 25
$822.4M
$298.1M
Q1 25
$765.2M
$317.9M
Q4 24
$732.8M
$305.5M
Q3 24
$577.2M
Q2 24
$516.7M
$273.4M
Q1 24
$464.0M
$201.5M
Total Assets
ACAD
ACAD
IMMR
IMMR
Q4 25
$1.6B
Q3 25
$1.3B
Q2 25
$1.2B
$1.1B
Q1 25
$1.1B
$1.4B
Q4 24
$1.2B
$1.4B
Q3 24
$976.9M
Q2 24
$914.1M
$1.2B
Q1 24
$855.1M
$244.7M
Debt / Equity
ACAD
ACAD
IMMR
IMMR
Q4 25
Q3 25
Q2 25
0.35×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ACAD
ACAD
IMMR
IMMR
Operating Cash FlowLast quarter
$-48.7M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-0.18×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ACAD
ACAD
IMMR
IMMR
Q4 25
$-48.7M
Q3 25
$74.3M
Q2 25
$64.0M
Q1 25
$20.3M
$-43.7M
Q4 24
$40.4M
Q3 24
$63.2M
Q2 24
$25.0M
$-85.9M
Q1 24
$29.1M
$29.9M
Free Cash Flow
ACAD
ACAD
IMMR
IMMR
Q4 25
Q3 25
$73.9M
Q2 25
Q1 25
$-46.2M
Q4 24
Q3 24
$63.2M
Q2 24
Q1 24
FCF Margin
ACAD
ACAD
IMMR
IMMR
Q4 25
Q3 25
26.5%
Q2 25
Q1 25
-9.8%
Q4 24
Q3 24
25.2%
Q2 24
Q1 24
Capex Intensity
ACAD
ACAD
IMMR
IMMR
Q4 25
Q3 25
0.1%
Q2 25
Q1 25
0.5%
Q4 24
Q3 24
0.0%
Q2 24
Q1 24
Cash Conversion
ACAD
ACAD
IMMR
IMMR
Q4 25
-0.18×
Q3 25
1.03×
Q2 25
2.40×
Q1 25
1.07×
-1.82×
Q4 24
0.28×
Q3 24
1.93×
Q2 24
0.75×
-3.25×
Q1 24
1.76×
1.60×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ACAD
ACAD

Nuplazid$174.4M61%
Daybue$109.6M39%

IMMR
IMMR

Course Material Sale$150.9M40%
General Merchandise Sale$138.0M37%
Rental Services$51.8M14%
Services And Other Revenue$25.6M7%
Per Unit Royalties$1.8M0%

Related Comparisons